Lazarex, ORIEN partnership hopes to expand cancer patients in clinical trials

Lazarex Cancer Foundation and Oncology Research Information Exchange Network (ORIEN) have partnered to improve access to clinical trials by cancer patients via the IMPACT program (Improving Patient Access to Cancer Clinical Trials).

As a response to Vice President Joe Biden’s national Cancer Moonshot initiative to condense 10 years of cancer prevention, diagnostics and treatment research into five years to end cancer in America, the Lazarex-ORIEN partnership to improve patient care and outcomes through clinical trials.

"This initiative is the first step toward creating a sustainable transformation in the 'bench-to-bedside' process for clinical trial enrollment," said Lazarex President Dana Dornsife.

By utilizing the IMPACT program, the partnership is able to reach more eligible patients to improve enrolment, retention and minority participation of cancer patients. Combining the data from academic institutions, medial facility, policy makers and public health organizations, the ORIEN networks is able to reach an additional 2,600 patients. The estimated budget each year is set to reach $7.5 million, for a total of more than $21 million over a three-year period.